Zeynep BAYRAMOĞLU, Yaşar ÜNLÜ, Ayşe Nur UĞUR KILINÇ, Ethem ÖMEROĞLU

What GATA-3 told us in breast carcinoma? 2 Years of single tertiary center experience

Aim: Our study aims to find the relationship between the degree of GATA-3 expression in breast cancer and other prognostic factors such as ER, PR, HER-2, Ki67, and axillary metastasis. Materials and Methods: The cases in which GATA-3 immunohistochemical staining was applied to breast cancer tissues between 2018 and 2020 were detected. Immunohistochemically stained preparations of ER, PRG, GATA-3, Ki-67, and HER-2 of these cases were obtained from the hospital archive and evaluated by two pathologists. Results: As a result, GATA-3 was directly proportional to PR and ER and inversely proportional to Ki 67. GATA-3 expression was associated with a higher Ki-67 mitotic index compared to the percentage of ER and PR expression. Conclusion: According to the results of our study, indicating GATA-3 positivity and negativity as well as the degree of expression in the pathology reports of breast tumors will help the clinician in terms of differentiation and prognosis of the tumor. Finally, breast tumors with high GATA-3 loss should be evaluated as more primitive tumors and the patients with these tumors should be followed up more closely.

PDF

___

1. Ko LJ, Engel JD. DNA-binding specificities of the GATA transcription factor family. Mol Cell Biol 1993;13:4011- 22.
2. Pai SY, Truitt ML, Ting CN, et al. Critical roles for transcription factor GATA-3 in thymocyte development. Immunity 2003;19:863-75.
3. Asselin-Labat ML, Sutherland KD, Barker H, et al. Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation. Nat Cell Biol. 2007;9:201-9.
4. Asselin-Labat ML, Sutherland KD, Vaillant F, et al. Gata-3 negatively regulates the tumor-initiating capacity of mammary luminal progenitor cells and targets the putative tumor suppressor caspase-14. Mol Cell Biol 2011;31:4609-22.
5. Miettinen M, McCue PA, Sarlomo-Rikala M, et al. GATA3: a multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors. Am J Surg Pathol 2014;38:13-22.
6. Brunelli M, Erdini F, Cima L, et al. Proximal CD13 Versus Distal GATA-3 Expression in Renal Neoplasia According to WHO 2016 Classification. Appl Immunohistochem Mol Morphol 2018;26:316-23.
7. Schwartz LE, Begum S, Westra WH, et al. GATA3 immunohistochemical expression in salivary gland neoplasms. Head Neck Pathol 2013;7:311-5.
8. Liu H, Shi J, Wilkerson ML, et al. Immunohistochemical evaluation of GATA3 expression in tumors and normal tissues: a useful immunomarker for breast and urothelial carcinomas. Am J Clin Pathol 2012;138:57- 64.
9. Mehra R, Varambally S, Ding L, et al. Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis. Cancer Res 2005;65:11259-64.
10. Yoon NK, Maresh EL, Shen D, et al. Higher levels of GATA3 predict better survival in women with breast cancer. Hum Pathol 2010;41:1794-801.
11. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424.
12. Auvinen P, Tammi R, Kosma VM, et al. Increased hyaluronan content and stromal cell CD44 associate with HER2 positivity and poor prognosis in human breast cancer. Int J Cancer 2013;132:531-9.
13. Furuya M, Horiguchi J, Nakajima H, et al. Correlation of L-type amino acid transporter 1 and CD98 expression with triple negative breast cancer prognosis. Cancer Sci 2012;103:382-9.
14. Witkiewicz AK, Dasgupta A, Sammons S, et al. Loss of stromal caveolin-1 expression predicts poor clinical outcome in triple negative and basal-like breast cancers. Cancer Biol Ther 2010;10:135-43.
15. He J, Peng R, Yuan Z, et al. Prognostic value of androgen receptor expression in operable triplenegative breast cancer: a retrospective analysis based on a tissue microarray. Med Oncol 2012;29:406-10.
16. Liu CG, Lu Y, Wang BB, et al. Clinical implications of stem cell gene Oct-4 expression in breast cancer. Ann Surg 2011;253:1165-71.
17. Nagai MA, Gerhard R, Fregnani JH, et al. Prognostic value of NDRG1 and SPARC protein expression in breast cancer patients. Breast Cancer Res Treat 2011;126:1-14.
18. de Kruijf EM, Sajet A, van Nes JG, et al. HLA-E and HLA-G expression in classical HLA class I-negative tumors is of prognostic value for clinical outcome of early breast cancer patients. J Immunol 2010;185:7452-9.
19. Baptista MZ, Sarian LO, Derchain SF, et al. Prognostic significance of PD-L1 and PD-L2 in breast cancer. Hum Pathol 2016;47:78-84.
20. Tan PH, Ellis I, Allison K, et al. WHO Classification of Tumours Editorial Board. The 2019 World Health Organization classification of tumours of the breast. Histopathology 2020;77:181-5.
21. Shaoxian T, Baohua Y, Xiaoli X, et al. Characterisation of GATA3 expression in invasive breast cancer: differences in histological subtypes and immunohistochemically defined molecular subtypes. J Clin Pathol 2017;70:926-34.